Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian I Rini

Showing results (31-40 of 401) with videos related to

Pageof 41
Sort By:
Cancer|September 8, 2011
Determining the optimal dose and schedule of sunitinib: some answers, more questionsCristina Suarez, Brian I Rini
Expert Opinion on Emerging Drugs|May 7, 2010
Emerging drugs for renal cell carcinomaLeticia Varella, Brian I Rini
European Urology Focus|April 18, 2025
Undertreatment or Overtreatment in the Adjuvant Setting for M1 No Evidence of Disease in Renal Cell Carcinoma: A Clinical ConundrumWesley Yip, Brian I Rini
Expert Opinion on Emerging Drugs|October 4, 2016
Emerging growth factor receptor antagonists for the treatment of renal cell carcinomaHaris Zahoor, Brian I Rini
Clinical Genitourinary Cancer|January 24, 2007
Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapiesSaby George, Brian I Rini
Cancer|June 22, 2019
Adjuvant therapy in renal cell carcinomaAnita Gul, Brian I Rini
Thescientificworldjournal|July 11, 2007
The role of targeted therapy in metastatic renal cell carcinomaJaya Unnithan, Brian I Rini
The New England Journal of Medicine|June 27, 2019
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. ReplyBrian I Rini, Thomas Powles
Urologic Oncology|September 9, 2008
Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinomaBrian I Rini, Keith Flaherty
Seminars in Oncology|August 27, 2013
Biology and treatment of advanced renal cell carcinoma: a global perspectiveBrian I Rini, Tom Powles
Pageof 41

Showing results (31-40 of 401) with videos related to

Sort By:
Pageof 41
Cancer|September 8, 2011
Determining the optimal dose and schedule of sunitinib: some answers, more questionsCristina Suarez, Brian I Rini
Expert Opinion on Emerging Drugs|May 7, 2010
Emerging drugs for renal cell carcinomaLeticia Varella, Brian I Rini
European Urology Focus|April 18, 2025
Undertreatment or Overtreatment in the Adjuvant Setting for M1 No Evidence of Disease in Renal Cell Carcinoma: A Clinical ConundrumWesley Yip, Brian I Rini
Expert Opinion on Emerging Drugs|October 4, 2016
Emerging growth factor receptor antagonists for the treatment of renal cell carcinomaHaris Zahoor, Brian I Rini
Clinical Genitourinary Cancer|January 24, 2007
Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapiesSaby George, Brian I Rini
Cancer|June 22, 2019
Adjuvant therapy in renal cell carcinomaAnita Gul, Brian I Rini
Thescientificworldjournal|July 11, 2007
The role of targeted therapy in metastatic renal cell carcinomaJaya Unnithan, Brian I Rini
The New England Journal of Medicine|June 27, 2019
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. ReplyBrian I Rini, Thomas Powles
Urologic Oncology|September 9, 2008
Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinomaBrian I Rini, Keith Flaherty
Seminars in Oncology|August 27, 2013
Biology and treatment of advanced renal cell carcinoma: a global perspectiveBrian I Rini, Tom Powles
Pageof 41